Hospital

In an analysis of data from 2 patient cohorts included in the phase 2 BYLieve study, investigators found that the data may indicate an increased dependence on the mutant PI3K-α.

Results from a phase 3b study showed that venetoclax combined with azacitidine or decitabine can safely be initiated in a US community-based outpatient setting.

Renin-angiotensin-aldosterone system inhibitors found to reduce the risk of an aneurysm rupture by 18%.

Medication adherence is critical to control the symptoms of congestive heart failure.

The American Society of Health-System Pharmacists’ conference includes educational opportunities that feature the latest products, services, and technology in the industry.

JZP458, a recombinant Erwinia-derived ASNase from a Pseudomonas fluorescens expression platform, was previously approved by the FDA for patients with ALL/LBL who had developed hypersensitivity to Escherichia coli (E. coli)–derived ASNase.

Investigators reported that individuals who completed 10 cycles of lurbinectedin and doxorubicin who then switched to lurbinectedin as a monotherapy tended to have maintained or improved tumor response.

Investigators found that individuals receiving selinexor had a median PFS of 5.7 months compared to 3.8 months for those given the placebo, with a stratification adjusted hazard ratio of 0.70.

The ability to measure GFR would be a significant advancement for clinicians in the United States.

The FDA Vaccines and Related Biological Products Advisory Committee voted nearly unanimously for an emergency use authorization for the Novavax COVID-19 vaccine, NVX-CoV2373, for use in individuals 18 years of age and older.

Scot Ebbinghaus, MD, vice president of oncology clinical research at Merck, discussed the growing body of research surrounding pembrolizumab (Keytruda) and what it is currently being investigated for.

Mentorship in pharmacy is particularly important because it may contribute to the development of competent, proficient, and motivated pharmacists to lead the profession and continue to advance the field.

Additionally, the 2-time dependent variables, dose reduction, and relative dose intensity 2 (RDI2) were included in the respective model as covariates to explore the connection to overall survival.

Overall, the investigators observed that the CR, undetectable minimal residual disease rates, progression free survival, and overall survival amomg the patients enrolled in the trial were favorable.

It is vital to have a robust controlled substance monitoring program to promptly identify and mitigate drug diversion.

Inclisiran (Leqvio) is a small interfering ribonucleic acid approved by the FDA for patients who are on a maximally-tolerated dose of statins and need additional LDL-C reduction.

In a collaboration using a neutral zone, organizations do not have access to each other’s data, but will instead have access to insights gathered by pooling their data together with other organizations for analysis by artificial intelligence technology.

Self-audits help onsite frontline pharmacy leaders and team members to assess compliance before an external surveyor enters their pharmacy to inspect medication use processes.

In addition to the new approval for rheumatoid arthritis, Riabni has already been approved for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.

Fosamprenavir calcium (Lexiva ) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Beth Koselke, PharmD, BCOP, discusses the impact of pharmacist intervention in clinical trial enrollment, specifically in the MYLUNG Consortium.

As pharmacists’ role in the health of communities continues to grow, it becomes even more critical for pharmacists to be armed with advanced technology when providing drug analysis.

All individuals who received second-line chemotherapy regimens met the PFS2 endpoint and all but 1 individual had died at time of data cutoff, according to a presentation at 2022 ASCO Annual Meeting.

Pharmacies can help bring inequities plaguing health care systems to an end to ensure the COVID-19 pandemic does not follow trends of inequity experienced in the HIV pandemic.

Rucaparib at the 400 mg dosage combined with nivolumab and ipilimumab for 4 cycles will continue onto a phase 2 trial for individuals with relapsed ovarian cancer.

Nicholas Robert, MD, chief medical officer at Ontada, discusses disparities in biomarker testing and how they are being addresses at ASCO 2022 Annual Meeting.

Biomarker positive patients were randomized to maintenance rucaparib 600 mg or matched placebo within 10 weeks of completing PBC until disease progression.

Analysis included a 29% objective response rate in cohort 4 of the C-144-01 study, the company says.